Cargando…
A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma
PURPOSE: Intratumoral interleukin-2 (IL-2) is effective but does not generate systemic immunity. Intravenous ipilimumab produces durable clinical response in a minority of patients, with potentially severe toxicities. Circulating anti-tumor T cells activated by ipilimumab may differ greatly from tum...
Autores principales: | Ray, Abhijit, Williams, Matthew A., Meek, Stephanie M., Bowen, Randy C., Grossmann, Kenneth F., Andtbacka, Robert H.I., Bowles, Tawnya L., Hyngstrom, John R., Leachman, Sancy A., Grossman, Douglas, Bowen, Glen M., Holmen, Sheri L., VanBrocklin, Matthew W., Suneja, Gita, Khong, Hung T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325451/ https://www.ncbi.nlm.nih.gov/pubmed/27391442 http://dx.doi.org/10.18632/oncotarget.10453 |
Ejemplares similares
-
Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study
por: Curti, Brendan D, et al.
Publicado: (2022) -
In vitro visualization and characterization of wild type and mutant IDH homo- and heterodimers using Bimolecular Fluorescence Complementation
por: Robinson, Gemma L., et al.
Publicado: (2016) -
Response to high dose ipilimumab plus temozolomide after progression on standard or low dose ipilimumab in advanced melanoma: a retrospective analysis
por: Williamson, Julie, et al.
Publicado: (2023) -
HBEGF promotes gliomagenesis in the context of Ink4a/Arf and Pten loss
por: Shin, Clifford H., et al.
Publicado: (2017) -
BRAF(V600E) induces reversible mitotic arrest in human melanocytes via microRNA-mediated suppression of AURKB
por: McNeal, Andrew S, et al.
Publicado: (2021)